RU2019123160A - Способ модуляции активности инфламмасом и воспаления в легком - Google Patents
Способ модуляции активности инфламмасом и воспаления в легком Download PDFInfo
- Publication number
- RU2019123160A RU2019123160A RU2019123160A RU2019123160A RU2019123160A RU 2019123160 A RU2019123160 A RU 2019123160A RU 2019123160 A RU2019123160 A RU 2019123160A RU 2019123160 A RU2019123160 A RU 2019123160A RU 2019123160 A RU2019123160 A RU 2019123160A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- inflammasome
- patient
- binds
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 43
- 210000004072 lung Anatomy 0.000 title claims 7
- 206010061218 Inflammation Diseases 0.000 title claims 5
- 230000004054 inflammatory process Effects 0.000 title claims 5
- 230000000694 effects Effects 0.000 title claims 3
- 108010034143 Inflammasomes Proteins 0.000 claims 16
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 6
- 206010069351 acute lung injury Diseases 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 210000005265 lung cell Anatomy 0.000 claims 6
- 102000002164 CARD domains Human genes 0.000 claims 4
- 108050009503 CARD domains Proteins 0.000 claims 4
- 102100035904 Caspase-1 Human genes 0.000 claims 4
- 108090000426 Caspase-1 Proteins 0.000 claims 4
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 claims 4
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims 4
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 claims 4
- 102000003810 Interleukin-18 Human genes 0.000 claims 4
- 108090000171 Interleukin-18 Proteins 0.000 claims 4
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 claims 4
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 claims 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 4
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 claims 4
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 229920000669 heparin Polymers 0.000 claims 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims 4
- 208000020431 spinal cord injury Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 108010076667 Caspases Proteins 0.000 claims 3
- 102000011727 Caspases Human genes 0.000 claims 3
- 101710136259 E3 ubiquitin-protein ligase XIAP Proteins 0.000 claims 3
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 210000004901 leucine-rich repeat Anatomy 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000007115 recruitment Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 2
- 102000055207 HMGB1 Human genes 0.000 claims 2
- 108700010013 HMGB1 Proteins 0.000 claims 2
- 101150021904 HMGB1 gene Proteins 0.000 claims 2
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims 2
- 102100032361 Pannexin-1 Human genes 0.000 claims 2
- 101710165201 Pannexin-1 Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960000610 enoxaparin Drugs 0.000 claims 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000008719 thickening Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 102000012064 NLR Proteins Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440180P | 2016-12-29 | 2016-12-29 | |
| US62/440,180 | 2016-12-29 | ||
| PCT/US2017/068713 WO2018126009A1 (en) | 2016-12-29 | 2017-12-28 | Method for modulating inflammasome activity and inflammation in the lung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019123160A true RU2019123160A (ru) | 2021-01-29 |
| RU2019123160A3 RU2019123160A3 (cg-RX-API-DMAC7.html) | 2021-01-29 |
Family
ID=62710025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019123160A RU2019123160A (ru) | 2016-12-29 | 2017-12-28 | Способ модуляции активности инфламмасом и воспаления в легком |
Country Status (16)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| US20190336598A1 (en) | 2016-12-29 | 2019-11-07 | University Of Miami | Methods for modulating inflammasome activity and inflammation in the lung |
| KR20210071944A (ko) * | 2018-07-03 | 2021-06-16 | 더 유니버시티 오브 마이애미 | 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 |
| US20220334127A1 (en) * | 2019-03-13 | 2022-10-20 | Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) | In vitro method for obtaining clinical data in patients suffering from an inflammatory disease |
| WO2021097084A1 (en) * | 2019-11-12 | 2021-05-20 | The Uab Research Foundation | Methods for treating immunosuppression and diseases associated with immunosuppression |
| CN111363847B (zh) * | 2020-02-12 | 2021-06-29 | 广州微远医疗器械有限公司 | 基于CRISPR技术的2019-nCoV快速检测引物组及其用途 |
| CN113278730B (zh) * | 2020-02-20 | 2022-03-25 | 中元汇吉生物技术股份有限公司 | 一种新型冠状病毒检测试剂盒、用途及其使用方法 |
| CN121177307A (zh) * | 2020-03-19 | 2025-12-23 | 南洋理工大学 | 包含nlrp1炎性体激活抑制剂的化合物或组合物用于治疗人气道炎症的用途 |
| CN111289745A (zh) * | 2020-03-25 | 2020-06-16 | 中山生物工程有限公司 | 新型冠状病毒IgM抗体酶联免疫检测试剂盒及其检测方法 |
| KR102658146B1 (ko) * | 2020-03-26 | 2024-04-18 | 경북대학교 산학협력단 | Pannexin3을 포함하는 근육 손상 진단용 바이오마커 조성물 및 이를 이용한 진단방법 |
| US20230296626A1 (en) * | 2020-04-27 | 2023-09-21 | University Of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| CN111529707B (zh) * | 2020-04-29 | 2021-04-23 | 威海市立医院 | Gsdmd抑制剂在制备治疗幽门螺杆菌感染的药物中的应用 |
| CN111777684A (zh) * | 2020-06-09 | 2020-10-16 | 重庆君同生物技术有限公司 | 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用 |
| EP4179069A4 (en) * | 2020-07-09 | 2024-10-02 | Remedy Cell Ltd. | METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY INFLAMMATION AND CYTOKINE STORM SYNDROME |
| KR102582417B1 (ko) * | 2020-11-06 | 2023-09-26 | 한국과학기술원 | 인플라마솜 어댑터 단백질(asc)의 중합체화 도메인에 결합하는 신규한 폴리펩타이드 및 이의 용도 |
| KR102549520B1 (ko) | 2021-01-29 | 2023-07-03 | 일리미스테라퓨틱스 주식회사 | 비염증성 식세포작용 유도 활성을 갖는 융합분자 |
| CN113109569B (zh) * | 2021-03-05 | 2022-08-19 | 李朴 | Gsdmd作为生物标志物在胸腔积液相关疾病鉴别诊断及疗效评估上的用途 |
| KR102673132B1 (ko) * | 2021-04-20 | 2024-06-12 | 아주대학교산학협력단 | 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드 |
| WO2022240757A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
| CN118119644A (zh) * | 2021-08-25 | 2024-05-31 | R.P.谢勒技术有限责任公司 | 具有人源化框架区的抗体 |
| CN115819548B (zh) * | 2021-11-16 | 2023-09-01 | 北京美德泰康生物科技有限公司 | 一种检测炎症相关疾病的标志物和方法 |
| WO2024006457A1 (en) * | 2022-06-29 | 2024-01-04 | University Of South Florida | Method of treating long-covid induced neurologic diseases |
| WO2024114906A1 (en) | 2022-11-30 | 2024-06-06 | Mabylon Ag | Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof |
| WO2024248287A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물 |
| WO2025081130A1 (en) * | 2023-10-12 | 2025-04-17 | University Of Miami | Use of anti-asc antibody in the treating of ocular disorders |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| KR101194446B1 (ko) | 2004-04-29 | 2012-10-24 | 오쓰까 세이야꾸 가부시키가이샤 | 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법 |
| EP1812062B1 (en) | 2004-10-25 | 2022-03-09 | Merck Sharp & Dohme Corp. | Anti-addl antibodies and uses thereof |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| MX2009009194A (es) | 2007-02-27 | 2009-10-08 | Genentech Inc | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. |
| WO2009014863A2 (en) * | 2007-06-29 | 2009-01-29 | Thomas Jefferson University | Asc and pyrin-asc pyroptosomes and uses thereof |
| US8685400B2 (en) | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| US20100150938A1 (en) * | 2008-07-03 | 2010-06-17 | University Of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| US20120288474A1 (en) * | 2009-11-06 | 2012-11-15 | Protaffin Biotechnologie Ag | Composition for treatment of cxcl8-mediated lung inflammation |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| IT1406201B1 (it) | 2010-12-10 | 2014-02-14 | Univ Degli Studi Trieste | Biomarcatori per la diagnosi della sclerosi multipla |
| CA2826820A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Asc as marker for chronic obstructive pulmonary disease (copd) |
| JP6170071B2 (ja) | 2012-02-06 | 2017-07-26 | ユニバーシティ オブ マイアミ | Ｃｎｓ損傷についてのバイオマーカーとしての自然免疫タンパク質 |
| TWI480044B (zh) | 2012-03-16 | 2015-04-11 | Taichung Veterans General Hospital | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution |
| US20140314746A1 (en) * | 2013-03-13 | 2014-10-23 | Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine | Methods for treating or preventing fibrosis in subjects afflicted with scleroderma |
| BR112015028338A2 (pt) * | 2013-05-17 | 2017-07-25 | Genentech Inc | métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal |
| JP6359013B2 (ja) * | 2013-07-29 | 2018-07-18 | 国立大学法人 鹿児島大学 | １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
| AU2015204558B2 (en) * | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10143709B2 (en) * | 2014-05-06 | 2018-12-04 | Indiana University Research And Technology Corporation | Use of ASC and ASC-CM to treat ARDS, SARS, and MERS |
| US10261098B2 (en) | 2014-08-18 | 2019-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for diagnosis and management of neuro-immunological diseases |
| US20160263183A1 (en) | 2015-03-10 | 2016-09-15 | Brown University | Methods for treating lung disease |
| CN107531752B (zh) * | 2015-05-12 | 2022-05-10 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| BR112018003212A2 (pt) | 2015-08-17 | 2018-09-25 | Twi Biotechnology Inc | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 |
| KR101948048B1 (ko) | 2016-12-08 | 2019-02-14 | 한양대학교 에리카산학협력단 | 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물 |
| US20190336598A1 (en) * | 2016-12-29 | 2019-11-07 | University Of Miami | Methods for modulating inflammasome activity and inflammation in the lung |
| CN111356924A (zh) | 2017-09-20 | 2020-06-30 | 迈阿密大学 | 检测作为神经障碍生物标记的炎性体蛋白的方法 |
| KR20210071944A (ko) | 2018-07-03 | 2021-06-16 | 더 유니버시티 오브 마이애미 | 인플라마솜 관련 질환 또는 상태 치료용 조성물 및 방법 |
-
2017
- 2017-12-28 US US16/474,708 patent/US20190336598A1/en not_active Abandoned
- 2017-12-28 EP EP17888678.4A patent/EP3562506A4/en not_active Withdrawn
- 2017-12-28 AU AU2017386550A patent/AU2017386550A1/en not_active Abandoned
- 2017-12-28 BR BR112019013463-8A patent/BR112019013463A2/pt unknown
- 2017-12-28 CN CN201780087090.4A patent/CN110461356A/zh active Pending
- 2017-12-28 SG SG10202106385XA patent/SG10202106385XA/en unknown
- 2017-12-28 RU RU2019123160A patent/RU2019123160A/ru unknown
- 2017-12-28 WO PCT/US2017/068713 patent/WO2018126009A1/en not_active Ceased
- 2017-12-28 CA CA3048864A patent/CA3048864A1/en active Pending
- 2017-12-28 MX MX2019007916A patent/MX2019007916A/es unknown
- 2017-12-28 JP JP2019536086A patent/JP2020503345A/ja active Pending
- 2017-12-28 KR KR1020197022320A patent/KR20200013630A/ko not_active Ceased
-
2018
- 2018-07-03 US US16/026,482 patent/US10703811B2/en active Active
-
2019
- 2019-06-26 IL IL267685A patent/IL267685A/en unknown
- 2019-07-01 PH PH12019501549A patent/PH12019501549A1/en unknown
- 2019-07-24 ZA ZA2019/04861A patent/ZA201904861B/en unknown
- 2019-07-25 CO CONC2019/0008087A patent/CO2019008087A2/es unknown
-
2020
- 2020-04-13 US US16/847,054 patent/US10961306B2/en active Active
- 2020-04-23 US US16/856,407 patent/US11174307B2/en active Active
-
2021
- 2021-04-23 EP EP21792075.0A patent/EP4139348A4/en active Pending
- 2021-04-23 WO PCT/US2021/028847 patent/WO2021217004A2/en not_active Ceased
- 2021-04-23 JP JP2022564482A patent/JP2023515271A/ja active Pending
- 2021-04-23 CA CA3176518A patent/CA3176518A1/en active Pending
- 2021-06-25 US US17/358,582 patent/US20210324065A1/en not_active Abandoned
-
2022
- 2022-11-11 JP JP2022181180A patent/JP2023016835A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3562506A1 (en) | 2019-11-06 |
| US20190336598A1 (en) | 2019-11-07 |
| WO2021217004A2 (en) | 2021-10-28 |
| BR112019013463A2 (pt) | 2020-01-07 |
| EP4139348A2 (en) | 2023-03-01 |
| MX2019007916A (es) | 2019-12-05 |
| RU2019123160A3 (cg-RX-API-DMAC7.html) | 2021-01-29 |
| US20190002550A1 (en) | 2019-01-03 |
| KR20200013630A (ko) | 2020-02-07 |
| US20200347124A1 (en) | 2020-11-05 |
| CA3176518A1 (en) | 2021-10-28 |
| WO2021217004A3 (en) | 2021-12-16 |
| US20200308262A1 (en) | 2020-10-01 |
| EP4139348A4 (en) | 2024-08-14 |
| IL267685A (en) | 2019-08-29 |
| US11174307B2 (en) | 2021-11-16 |
| WO2018126009A1 (en) | 2018-07-05 |
| CO2019008087A2 (es) | 2019-10-21 |
| EP3562506A4 (en) | 2021-01-06 |
| JP2023016835A (ja) | 2023-02-02 |
| CA3048864A1 (en) | 2018-07-05 |
| SG10202106385XA (en) | 2021-07-29 |
| US10961306B2 (en) | 2021-03-30 |
| AU2017386550A1 (en) | 2019-08-08 |
| PH12019501549A1 (en) | 2020-02-24 |
| CN110461356A (zh) | 2019-11-15 |
| JP2023515271A (ja) | 2023-04-12 |
| US20210324065A1 (en) | 2021-10-21 |
| JP2020503345A (ja) | 2020-01-30 |
| US10703811B2 (en) | 2020-07-07 |
| ZA201904861B (en) | 2024-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019123160A (ru) | Способ модуляции активности инфламмасом и воспаления в легком | |
| JP2020503345A5 (cg-RX-API-DMAC7.html) | ||
| US11471507B2 (en) | HMGB1 antagonist | |
| JP6981878B2 (ja) | 抗菌療法 | |
| CN112375149B (zh) | Ace2免疫融合蛋白及其应用 | |
| Zhu et al. | High mobility group box 1 protein as a potential drug target for infection-and injury-elicited inflammation | |
| KR20180012856A (ko) | 면역반응의 조절을 위한 방법 및 폴리펩타이드 | |
| EP2532365A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
| EP2532366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER | |
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| RU2012139432A (ru) | Полипептиды | |
| EA201201114A1 (ru) | Агонистические dr5-связывающие полипептиды | |
| JP2011528332A (ja) | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 | |
| SA517390230B1 (ar) | Rgma بــروتــيــن رابــط لــ واســـتــخـدامـــه | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| JP2017515473A5 (cg-RX-API-DMAC7.html) | ||
| JP2013535965A5 (cg-RX-API-DMAC7.html) | ||
| US11124558B2 (en) | Use of tetranectin and peptide agonists to treat inflammatory diseases | |
| JP2024539138A (ja) | 多価効果を持つペプチド | |
| JP2019038772A5 (cg-RX-API-DMAC7.html) | ||
| US20220153826A1 (en) | Methods and compositions for treating virus-associated inflammation | |
| US11883461B2 (en) | HMGB1 antagonist treatment of severe sepsis | |
| CA3157785A1 (en) | Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof | |
| JP2018512844A5 (cg-RX-API-DMAC7.html) | ||
| CA3164760A1 (en) | Methods and compositions for evaluating and treating fibrosis |